Effect and tolerability of blonanserin in severe delusion with various types of dementia

Manabu Takaki, Hajime Honda, Seishi Terada, Yosuke Uchitomi

Research output: Contribution to journalArticle

Abstract

Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D2 receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D3 receptor-blocking activities and weak 5-hydroxytryptamine-2C, α1-, histamine H1-, and muscarinic M1-blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia. Psychogeriatrics

Original languageEnglish
Pages (from-to)144-146
Number of pages3
JournalPsychogeriatrics
Volume15
Issue number2
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Delusions
Dementia
Hallucinations
Dopamine D3 Receptors
Geriatric Psychiatry
Dopamine D2 Receptors
Serotonin Receptors
Cholinergic Agents
Histamine
Serotonin
Equipment and Supplies
Pharmaceutical Preparations
blonanserin

Keywords

  • Blonanserin
  • D<inf>3</inf> receptor
  • Delusion
  • Dementia
  • Hallucination

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Gerontology

Cite this

Effect and tolerability of blonanserin in severe delusion with various types of dementia. / Takaki, Manabu; Honda, Hajime; Terada, Seishi; Uchitomi, Yosuke.

In: Psychogeriatrics, Vol. 15, No. 2, 01.06.2015, p. 144-146.

Research output: Contribution to journalArticle

@article{55fb4001f99540c899a27d3842dcaa53,
title = "Effect and tolerability of blonanserin in severe delusion with various types of dementia",
abstract = "Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D2 receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D3 receptor-blocking activities and weak 5-hydroxytryptamine-2C, α1-, histamine H1-, and muscarinic M1-blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia. Psychogeriatrics",
keywords = "Blonanserin, D<inf>3</inf> receptor, Delusion, Dementia, Hallucination",
author = "Manabu Takaki and Hajime Honda and Seishi Terada and Yosuke Uchitomi",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/psyg.12090",
language = "English",
volume = "15",
pages = "144--146",
journal = "Psychogeriatrics",
issn = "1346-3500",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Effect and tolerability of blonanserin in severe delusion with various types of dementia

AU - Takaki, Manabu

AU - Honda, Hajime

AU - Terada, Seishi

AU - Uchitomi, Yosuke

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D2 receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D3 receptor-blocking activities and weak 5-hydroxytryptamine-2C, α1-, histamine H1-, and muscarinic M1-blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia. Psychogeriatrics

AB - Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D2 receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D3 receptor-blocking activities and weak 5-hydroxytryptamine-2C, α1-, histamine H1-, and muscarinic M1-blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia. Psychogeriatrics

KW - Blonanserin

KW - D<inf>3</inf> receptor

KW - Delusion

KW - Dementia

KW - Hallucination

UR - http://www.scopus.com/inward/record.url?scp=84930762892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930762892&partnerID=8YFLogxK

U2 - 10.1111/psyg.12090

DO - 10.1111/psyg.12090

M3 - Article

AN - SCOPUS:84930762892

VL - 15

SP - 144

EP - 146

JO - Psychogeriatrics

JF - Psychogeriatrics

SN - 1346-3500

IS - 2

ER -